➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Boehringer Ingelheim
McKinsey
Dow
Baxter

Last Updated: August 3, 2020

DrugPatentWatch Database Preview

BLEOMYCIN SULFATE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Bleomycin Sulfate patents expire, and what generic alternatives are available?

Bleomycin Sulfate is a drug marketed by Cipla, Fresenius Kabi Usa, Hospira, Meitheal, Pharmachemie Bv, Teva Parenteral, Teva Pharms Usa, and West-ward Pharms Int. and is included in eight NDAs.

The generic ingredient in BLEOMYCIN SULFATE is bleomycin sulfate. There are six drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bleomycin sulfate profile page.

US ANDA Litigation and Generic Entry Outlook for Bleomycin Sulfate

A generic version of BLEOMYCIN SULFATE was approved as bleomycin sulfate by HOSPIRA on March 10th, 2000.

  Start Trial

Drug patent expirations by year for BLEOMYCIN SULFATE
Recent Clinical Trials for BLEOMYCIN SULFATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The EMMES CorporationPhase 1
AIDS Malignancy ConsortiumPhase 1
University of ArkansasPhase 1

See all BLEOMYCIN SULFATE clinical trials

Pharmacology for BLEOMYCIN SULFATE
Medical Subject Heading (MeSH) Categories for BLEOMYCIN SULFATE

US Patents and Regulatory Information for BLEOMYCIN SULFATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cipla BLEOMYCIN SULFATE bleomycin sulfate INJECTABLE;INJECTION 209439-001 Mar 11, 2019 AP RX No No   Start Trial   Start Trial   Start Trial
Meitheal BLEOMYCIN SULFATE bleomycin sulfate INJECTABLE;INJECTION 205030-002 Apr 20, 2018 AP RX No No   Start Trial   Start Trial   Start Trial
Hospira BLEOMYCIN SULFATE bleomycin sulfate INJECTABLE;INJECTION 065031-001 Mar 10, 2000 AP RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Colorcon
Johnson and Johnson
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.